Multicenter Study of Antimicrobial Resistance of Gram-positive and Gram-negative Clinical Strains to Ceftaroline and Other Antimicrobials in Russia (CERBERUS)

AstraZeneca

Status: Completed

Conditions: Bacterial Skin Diseases

Study type: Observational

Funder types: Industry

Identifiers

NCT01700842

NIS-IRU-XXX-2012/1

Details and patient eligibility

About

Approximately 3,000 of clinically significant isolates of different species from respective respective sources in geographically distinct Russian cities will be collected and tested on ceftaroline and other antimicrobials.

Enrollment: 3,000 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Isolates derived from patients' clinical material will be included in the study
• Isolates collected retro- and prospectively will be included in the study (from 01.01.2008 till 31.12.2012)
• Isolates, allocated of a clinical material of adult patients (> 18 years), should make not less than 70 % from total number of included isolates)
• All included isolates should be unique: only one isolate can be included in the study of each biological type from each patient
• All isolates should correspond to clinic-laboratory criteria of the etiologic importance, i.e. should be derived from patients with infection symptoms from the corresponding clinical material
• Case report form (CRF) (Appendix 1) should be correctly completed for each isolate

Exclusion criteria

• ESBL-producing representatives of Enterobacteriaceae (ESBL-Extended-spectrum beta-lactamase)
• Isolates, arrived in the central laboratory contaminated or unviable